Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006

Journal of Obstetrics and Gynaecology Research

Volumn 34, Issue 4, 2008, Pages 561-566

  Fan, Shang Rong ^a   Liu, Xiao Ping ^a   Li, Jian Wu ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Antifungal susceptibility; Classification; Vulvovaginal candidiasis

Indexed keywords

CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN;

ADULT; AGAR DIFFUSION; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHINA; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; SACCHAROMYCES CEREVISIAE; UNIVERSITY HOSPITAL; VAGINA CANDIDIASIS;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; CHINA; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES;

EID: 50049136345     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2008.00817.x     Document Type: Article

References (24)

1. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapy considerations. Am J Obstet Gynecol 1998 178 : 203 211.
2. Sobel JD, Zervos M, Reed BD et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated candida vaginitis: Clinical implications. Antimicrob Agents Chemother 2003 47 : 34 38.
3. Barnhart K. Safety and efficacy of bedtime versus day-time administration of the miconazole nitrate 1200 mg. vaginal ovule insert to treat vulvovaginal candidiasis. Curr Med Res Opin 2005 21 : 127.
4. Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994 32 : 267 274.
5. Corsello S, Spinillo A, Osnengo G et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003 110 : 66 72.
6. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005 43 : 2155 2162.
7. Bauters TGM, Dhont MA, Temmerman MIL, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconzole in women. Am J Obstet Gynecol 2002 187 : 569 574.
8. Kwok YK, Tay YK, Goh CL, Kamarudin A, Koh MT, Seow CS. Epidemiology and in vitro activity of antimycotics against candidal vaginal/skin/nail infections in Singapore. Int J Dermatol 1998 37 : 145 149.
9. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): A systematic review. BJOG 2002 109 : 85 95.
10. Sobel JD, Kapernick PS, Zervos M et al. Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001 185 : 363 369.
11. CDC. Sexually transmitted diseases treatment guideline 2006. MMWR 2006 55 : RR 11.
12. Users Guide to Neo-Sensitabs, 18th edn. Taastrup, Denmark : Rosco, 2005/2006 150.
13. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Guideline. Document M44-A. Wayne, PA : Clinical and Laboratory Standards Institute, 2004.
14. Holland J, Young ML, Lee O, Chen CA. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 2003 79 : 249 250.
15. Spinillo A, Capuzzo E, Egbe TO, Baltaro F, Nicola S, Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol 1995 85 : 993 998.
16. Arzeni D, Del Poeta M, Simonetti O et al. Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur J Epidemiol 1997 13 : 447 450.
17. Costa M, Passos XS, Miranda ATB, Araujo RSC, Paula CR, Silva MRR. Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis. Mycopathologia 2004 157 : 43 47.
18. Lynch ME, Sobel JD, Fidel PL Jr. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol 1996 34 : 337 339.
19. Fan SR, Liu XP. Nonalbicans Candida species and antifungal susceptibility. Int J Gynecol Obstet 2007 98 : 158 159.
20. Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: Epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002 35 : 1066 1070.
21. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003 189 : 1297 1300.
22. Fan SR, Liu XP. In vitro miconazole susceptibility and clinical outcome in vulvovaginal candidiasis. Int J Gynaecol Obstet 2007 97 : 207 208.
23. Consolaro MEL, Albertoni TA, Svidzinski AE, Peralta RM, Svidzinski TIE. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia 2005 159 : 501 507.
24. Sojakova M, Liptajova D, Borovsky M, Subik J. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 2004 157 : 163 169.